Loading...
•
Sep 30, 2022
Curis Q3 2022 Earnings Report
Curis reported a net loss for Q3 2022 and focused its resources on advancing emavusertib development.
Key Takeaways
Curis reported a net loss of $13.3 million for the third quarter of 2022, compared to a net loss of $11.1 million for the same period in 2021. The company is prioritizing the development of emavusertib and expects its cash runway to extend into 2025.
Curis is focusing its resources to drive the development of emavusertib.
Cash runway extended into 2025 due to reallocation of resources.
Data from the TakeAim Leukemia trial of emavusertib will be presented at ASH 2022.
FDA allowed enrollment to resume in the TakeAim Lymphoma study and in the monotherapy dose finding phase of the TakeAim Leukemia study.
Curis
Curis
Curis Revenue by Segment
Revenue by Segment
Royalties Revenue
CapyFin.com Forward Guidance
Curis expects that its existing cash, cash equivalents and investments should enable it to maintain its planned operations into 2025.